CO106 Efficacy of FDA-Approved Disease-Modifying Therapies (DMTS) Versus Active Comparator Medications for Relapsing-Remitting Multiple Sclerosis: A Systematic Review
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.202
https://www.valueinhealthjournal.com/article/S1098-3015(22)00403-X/fulltext
Title :
CO106 Efficacy of FDA-Approved Disease-Modifying Therapies (DMTS) Versus Active Comparator Medications for Relapsing-Remitting Multiple Sclerosis: A Systematic Review
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00403-X&doi=10.1016/j.jval.2022.04.202
First page :
Section Title :
Open access? :
No
Section Order :
10173